BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells

April 13, 2017
Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified antigen-specific regulatory T cells (Tregs), TxCell expects to start a first-in-man study of a candidate from its next generation Treg platform in 2018. Mr. Stephane Boissel, TxCell’s CEO, explained to Scrip’s Mike Ward why the company accelerated its new platform and how it intends to focus on inflammatory and autoimmune diseases.
Previous Video
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies
BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies

Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR...

Next Video
BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline
BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline

Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools a...